Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[3H]5-hydroxytryptamine binding sites in postmortem human brain.

S C Cheetham1, Y Yamaguchi, R W Horton

  • 1Department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, London, U.K.

Neuropharmacology
|October 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2014
Same author

Corticotropin-releasing factor immunoreactivity in post-mortem brain from depressed suicides.

Journal of psychopharmacology (Oxford, England)·2011
Same author

The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.

Neuropharmacology·2009
Same author

Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?

Experimental neurology·2005
Same author

Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.

The European journal of neuroscience·2005
Same author

Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine.

Neuropharmacology·2000
Same journal

Thyrotropin-releasing hormone and dopaminergic systems interact in the ventral tegmental area to regulate food intake in rats.

Neuropharmacology·2026
Same journal

TRPC5 as a modulator of TRPV1 signalling in pathological pain states.

Neuropharmacology·2026
Same journal

Loss of mGlu<sub>5</sub> receptors from PV inhibitory neurons attenuates sex differences in ethanol and sucrose seeking.

Neuropharmacology·2026
Same journal

PM289, a synthetic CB2 in vitro receptor agonist, modulates morphine-induced antinociceptive effect and withdrawal syndrome in an animal model of osteoarthritic pain.

Neuropharmacology·2026
Same journal

Purinergic-cytokine signaling as a regulatory axis in neuroimmune development.

Neuropharmacology·2026
Same journal

Acupuncture improves depressive symptoms and prefrontal cortical function in mild to moderate depressive disorder: A randomized sham-controlled trial and fNIRS study.

Neuropharmacology·2026
See all related articles

This study investigated serotonin (5-HT) binding sites in human brain regions. Results show 5-HT1-like sites are prevalent, with subtypes varying by brain area, and suggest additional uncharacterized 5-HT sites.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Serotonin (5-HT) receptors are crucial in brain function.
  • Understanding 5-HT receptor subtypes and distribution is key to developing targeted therapies.

Purpose of the Study:

  • To characterize the subtypes and distribution of [3H]5-hydroxytryptamine (5-HT) binding sites in postmortem human frontal cortex, hippocampus, and amygdala.
  • To investigate the selectivity of 5-HT drugs for different 5-HT receptor subtypes.

Main Methods:

  • Radioligand binding assays using [3H]5-hydroxytryptamine (5-HT).
  • Displacement studies with selective 5-HT receptor drugs (e.g., RU 24969, 8-OH-DPAT, mianserin).
  • Analysis of binding data to determine site density and affinity in different brain regions.

Main Results:

Related Experiment Videos

  • [3H]5-HT selectively labeled 5-HT1-like sites in the frontal cortex, with minimal labeling of 5-HT2 or 5-HT3 sites.
  • 5-HT1A subtype constituted approximately 40% of 5-HT1 sites in the frontal cortex and amygdala, and 60% in the hippocampus.
  • The drug RU 24969 showed higher affinity displacement of [3H]5-HT sites than 8-OH-DPAT across all studied regions, indicating the presence of additional, uncharacterized 5-HT sites.

Conclusions:

  • Human brain possesses distinct populations of 5-HT1-like binding sites, with regional variations in subtype composition (5-HT1A, 5-HT1C).
  • The findings highlight the complexity of serotonin receptor pharmacology and the need for further research into unidentified 5-HT binding sites.